SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February.
B. Riley Oncology Conference
Thursday, January 18, 2024
12:30PM PT/3:30PM ET
Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Wednesday, February 7, 2024
8:30AM PT/11:30AM ET
Oppenheimer 34th Annual Healthcare Life Sciences Conference
Wednesday, February 14, 2024
9:00AM PT/12:00PM ET
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, ...